JP2020523342A5 - - Google Patents

Download PDF

Info

Publication number
JP2020523342A5
JP2020523342A5 JP2019568236A JP2019568236A JP2020523342A5 JP 2020523342 A5 JP2020523342 A5 JP 2020523342A5 JP 2019568236 A JP2019568236 A JP 2019568236A JP 2019568236 A JP2019568236 A JP 2019568236A JP 2020523342 A5 JP2020523342 A5 JP 2020523342A5
Authority
JP
Japan
Prior art keywords
weight
composition
mass
baicalein
oroxylin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019568236A
Other languages
English (en)
Japanese (ja)
Other versions
JP7209645B2 (ja
JP2020523342A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/037454 external-priority patent/WO2018232063A1/en
Publication of JP2020523342A publication Critical patent/JP2020523342A/ja
Publication of JP2020523342A5 publication Critical patent/JP2020523342A5/ja
Application granted granted Critical
Publication of JP7209645B2 publication Critical patent/JP7209645B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019568236A 2017-06-15 2018-06-14 βセクレターゼの阻害のための組成物および方法 Active JP7209645B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762520141P 2017-06-15 2017-06-15
US62/520,141 2017-06-15
PCT/US2018/037454 WO2018232063A1 (en) 2017-06-15 2018-06-14 Compositions and methods for beta secretase inhibition

Publications (3)

Publication Number Publication Date
JP2020523342A JP2020523342A (ja) 2020-08-06
JP2020523342A5 true JP2020523342A5 (https=) 2021-07-26
JP7209645B2 JP7209645B2 (ja) 2023-01-20

Family

ID=64655980

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019568236A Active JP7209645B2 (ja) 2017-06-15 2018-06-14 βセクレターゼの阻害のための組成物および方法
JP2019569247A Active JP6796217B2 (ja) 2017-06-15 2018-06-15 神経保護組成物とその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019569247A Active JP6796217B2 (ja) 2017-06-15 2018-06-15 神経保護組成物とその使用

Country Status (9)

Country Link
US (2) US11458117B2 (https=)
EP (2) EP3638277B1 (https=)
JP (2) JP7209645B2 (https=)
KR (2) KR20190134809A (https=)
CA (2) CA3063751C (https=)
ES (1) ES3005508T3 (https=)
FI (1) FI3638277T3 (https=)
PL (2) PL3638277T3 (https=)
WO (2) WO2018232063A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3005508T3 (en) * 2017-06-15 2025-03-14 Sami Labs Ltd Compositions and methods for beta secretase inhibition
US12465585B2 (en) * 2018-06-15 2025-11-11 Sami-Sabinsa Group Limited Compositions for the management of seizure induced neurotoxicity
CN110115712A (zh) * 2019-07-04 2019-08-13 兰州大学 一种同时激活氧化磷酸化通路和抑制糖酵解途径的激活剂及其应用
CN114630650B (zh) * 2019-08-26 2024-03-29 萨米-萨宾莎集团有限公司 植物活性物及其防污染效果
CN114246879B (zh) * 2021-12-30 2023-10-27 沈阳兴齐眼药股份有限公司 木蝴蝶苷b在制备用于预防、控制和/或治疗眼部疾病药物中的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101837003B (zh) * 2002-04-30 2013-09-04 尤尼根公司 作为治疗剂的包含无取代b环类黄酮和黄烷混合物的组合物
US8945518B2 (en) * 2002-04-30 2015-02-03 Unigen, Inc. Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions
US8034387B2 (en) * 2002-04-30 2011-10-11 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
MXPA06002456A (es) * 2003-09-02 2006-08-31 Unigen Pharmaceuticals Inc Formulacion de una mezcla de flavonoides con el aniillo b libre y flavanos para utilizarse en la prevencion y tratamiento de la declinacion cognoscitiva y el deterioro de la memoria relacionado con la edad.
US7855200B2 (en) * 2006-01-09 2010-12-21 Council Of Scientific And Industrial Research Method for treatment of gastric ulcers and ulcers induced by aspirin
JP2009527541A (ja) 2006-02-21 2009-07-30 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ 腸管αグルコシダーゼ阻害剤ならびにその単離方法およびその使用
US20100029654A1 (en) 2006-03-23 2010-02-04 Mount Sinai School Of Medicine Cardiovascular compositions and use of the same for the treatment of alzheimer's disease
KR20080008929A (ko) * 2006-11-20 2008-01-24 대한민국(관리부서 식품의약품 안전청장) 오록실린 a를 함유하는 인지 기능 장애 관련 질환의 예방및 개선용 건강기능식품
US20150231067A1 (en) * 2012-08-29 2015-08-20 Mannkind Corporation Method and composition for treating hyperglycemia
NZ753943A (en) * 2016-11-11 2021-03-26 Sami Labs Ltd Composition containing oroxylin a and method of extraction thereof
ES3005508T3 (en) 2017-06-15 2025-03-14 Sami Labs Ltd Compositions and methods for beta secretase inhibition

Similar Documents

Publication Publication Date Title
JP2020523342A5 (https=)
US20240350453A1 (en) Methods of treating neurological and psychiatric disorders
P Cardinali et al. Clinical aspects of melatonin intervention in Alzheimer's disease progression
FI3638277T3 (fi) Koostumukset ja menetelmät beetasekretaasin estämiseksi
JP2022531003A (ja) 結節性硬化症複合体の治療におけるカンナビジオールの使用
MX2008000250A (es) Combinaciones de eszopiclona y trans-4-(3,4-diclorofenil)-1,2,3,4- tetrahidro-n-metil-1-naftalenamina o trans 4-(3,4-diclorofenil)-1, 2,3,4-tetrahidro-1-naftalenamina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y
CZ355897A3 (cs) Způsob léčení mánie a bipolárních poruch
Gąsiorowski et al. Current and near-future treatment of Alzheimer’s disease
KR20200065012A (ko) 글리신 뇌병증 치료를 위한 벤조에이트 함유 조성물의 사용
JP4880223B2 (ja) スクシネートエステル誘導体の痴呆症の治療への使用
CN114870018A (zh) 炎症小体nlrp3抑制剂通过抑制神经系统炎症在制备治疗阿尔茨海默症药物中的应用
JP5341037B2 (ja) 双極性障害を処置するための医薬を得るためのアゴメラチンの使用
CN103156876A (zh) 一种治疗中枢神经系统疾病的药物组合物及其制备方法和用途
KR20210113240A (ko) 신경 변성 질환의 예방 또는 치료약
KR20060128961A (ko) 중추신경계 질환 또는 질병의 치료 및 관리를 위해탈리도미드를 사용하는 방법 및 조성물
KR20180129692A (ko) 홍경천 및 연자육을 포함하는 수면 장애 개선용 조성물
JP2024507940A (ja) 小児期発症てんかん症候群の治療におけるカンナビジオール及びクロバザムの使用
JP6465592B2 (ja) 涙液分泌促進組成物
CN111617255B (zh) 用于治疗中枢神经系统紊乱的组合疗法
JP7638004B2 (ja) 認知症の治療
KR102390613B1 (ko) 항암제 화합물을 유효성분으로 포함하는 알츠하이머성 치매의 예방 또는 치료용 조성물
CN112569217B (zh) 戊酸衍生物在治疗遗传性小脑共济失调中的应用
WO2025143100A1 (ja) 神経変性疾患治療剤
Esin et al. Influence of Standardized Extract Ginkgo biloba EGb761® Towards Quality of Life Indicators in Patients with Diabetes Mellitus Type 2
CN111671757A (zh) 3-[4-(4-吗啉基)-7h-吡咯并[2,3-d]嘧啶-5-基]苯甲腈制药用途